Dr.ย Weiliย Zhao
M.D., Ph.D.
Professor of Hematology & Vice President, Ruijin Hospital
corporate_fareRuijin Hospital, Shanghai Jiao Tong University School of Medicine
Weili Zhao
M.D., Ph.D.
Prof. Weili Zhao is a Professor of Hematology, First Deputy Director of the Shanghai Institute of Hematology, and Vice President of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China. She is internationally recognised for her clinical and research expertise in malignant lymphoma and precision haemato-oncology.
Prof. Zhao has been associated with the Department of Hematology at Ruijin Hospital for more than 25 years, building one of China's foremost lymphoma programmes. Her clinical work spans diffuse large B-cell lymphoma, NK/T-cell lymphoma, T-cell lymphoma, and other haematological malignancies, with a strong emphasis on molecular classification, biomarker-guided treatment planning, and targeted therapy. She completed advanced hematology training at Saint-Louis Hospital and University Paris VII in France in 2001, and continues to serve as a doctoral supervisor at both Shanghai Jiao Tong University and University Paris VII. She has authored more than 100 peer-reviewed publications in leading journals including Cancer Cell, Nature Genetics, Blood, The Lancet Haematology, and Clinical Cancer Research, and has received national and municipal awards for scientific and clinical achievement.
CancerFax can coordinate medical record review, second opinion preparation, and consultation support for international patients seeking an opinion from Prof. Zhao at Ruijin Hospital.
Why Consider Prof. Weili Zhao?
Prof. Weili Zhao combines deep clinical experience in haematological malignancies with internationally recognised translational research in lymphoma biology, making her a compelling choice for patients with complex or difficult-to-treat lymphoma subtypes.
Areas of Specialisation
Clinical and research expertise in lymphoma and haematological malignancies
Prof. Zhao's practice centres on malignant lymphoma and related haematological cancers, integrating molecular diagnostics, targeted therapy, and translational research into patient care.
Malignant Lymphoma
Comprehensive diagnosis, molecular classification, and treatment of lymphoid malignancies.
- arrow_rightMolecular subtyping and biomarker profiling
- arrow_rightImmunochemotherapy and novel agent combination regimens
- arrow_rightClinical trial-based treatment approaches
- arrow_rightGenomic and molecular analysis for diagnosis and classification
- arrow_rightTargeted treatment selection based on tumour biology
- arrow_rightMultidisciplinary management planning
- arrow_rightBroad coverage of haematological malignancies
- arrow_rightTumour microenvironment and progression analysis
Precision Haemato-Oncology
Molecular and genomic approaches to haematological cancer diagnosis and treatment planning.
- arrow_rightMolecular profiling to guide therapy selection
- arrow_rightIntegrated pathology and genomic review
- arrow_rightBTK inhibitor and novel targeted agent combinations
- arrow_rightHDAC inhibitor combination strategies
- arrow_rightTranslational research linking molecular findings to clinical outcomes
Clinical Procedures and Treatment Approaches
Lymphoma diagnosis, staging, and treatment services at Ruijin Hospital
Prof. Zhao's clinical services span the full spectrum of lymphoma care, from precision molecular diagnosis through to targeted and combination treatment strategies.
Lymphoma Diagnosis and Molecular Classification
DiagnosisAccurate lymphoma subtyping using molecular, genomic, and pathological profiling to guide treatment.
Targeted and Combination Therapy
Targeted TherapyMolecularly guided treatment regimens for lymphoma, incorporating targeted agents and novel combinations.
Medical Oncology for Haematological Malignancies
Medical OncologySystemic treatment planning and clinical management for lymphoid and other haematological cancers.
Second Opinion for Lymphoma Cases
Second OpinionExpert review of lymphoma diagnosis, pathology, and treatment plans, including complex or refractory cases.
Research and Publications
Translational lymphoma research and peer-reviewed academic contributions
Prof. Zhao has published more than 100 peer-reviewed articles in leading haematology and oncology journals. Her research spans molecular mechanisms in lymphoma, precision diagnosis, targeted therapy, and tumour biology.
Prof. Zhao's full publication list is available through the Shanghai Jiao Tong University School of Medicine faculty directory and PubMed.
Education & Training
Prof. Zhao completed her medical and doctoral training through Shanghai Jiao Tong University School of Medicine (formerly Shanghai Second Medical University) and undertook advanced haematology training at Saint-Louis Hospital and University Paris VII, France.
Clinical Experience
Prof. Zhao has spent her entire clinical and academic career at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, where she has been a central figure in the Department of Hematology for more than 25 years.
Languages & International
Prof. Zhao consults in the following languages. English and French proficiency are reported in an official Ruijin Hospital profile.
Prof. Zhao has English and French proficiency in addition to Chinese, reflecting her international academic training and research collaborations. CancerFax can support additional language requirements for international patients.
CancerFax can coordinate professional medical interpreter support for international patients where required.
How CancerFax Helps You Access Dr. Weili Zhao
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Weili Zhao's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Weili Zhao's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Weili Zhao before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Weili Zhao's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Weili Zhao's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Weili Zhao's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Weili Zhao
Prof. Weili Zhao specialises in haematological malignancies, with a particular focus on malignant lymphoma. Her clinical and research expertise includes diffuse large B-cell lymphoma (DLBCL), NK/T-cell lymphoma, T-cell lymphoma, and other lymphoid malignancies. She is based at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Prof. Zhao practises at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, which is one of China's foremost centres for haematology and translational cancer research. She also serves as First Deputy Director of the Shanghai Institute of Hematology and as Vice President of Ruijin Hospital.
CancerFax can assist international patients seeking an opinion or consultation with Prof. Zhao by coordinating medical record review, preparing case summaries, and managing communication with Ruijin Hospital, subject to availability and case acceptance. Teleconsultation and in-person appointment availability should be confirmed through CancerFax or directly with the hospital.
A second opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, molecular findings, and treatment history. CancerFax will review the documents, prepare a structured case summary, and coordinate the submission to Ruijin Hospital. The consultation format and response timeline depend on the hospital's availability and case review process.
Prof. Zhao has published more than 100 peer-reviewed articles in journals including Cancer Cell, Nature Genetics, Blood, The Lancet Haematology, and Clinical Cancer Research. Her research covers molecular mechanisms of lymphoma, genomic profiling, targeted therapy, and precision haemato-oncology. She has also participated in clinical trials involving novel treatment combinations for diffuse large B-cell lymphoma and other lymphoid malignancies.
Prof. Zhao's verified areas of treatment expertise include targeted therapy for lymphoma, biomarker-driven treatment planning, immunochemotherapy combinations such as R-CHOP and novel agent regimens, HDAC inhibitor-based strategies, and molecular classification of lymphoma subtypes to personalise care. She is also involved in clinical research evaluating new treatment combinations for previously untreated and high-risk lymphoma cases.
Connect with Weili Zhao Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.